On 23-24 July 2026, the US Food and Drug Administrations Pharmacy Compounding Advisory Committee recommended that six of seven peptides it assessed (BPC-157, KPV, TB-500,MOTS-c, epitalon and semax) be considered for inclusion on the section 503A Bulks List, potentially permitting their use in patient-specific compounded preparations.[2,7] The votes were close and advisory
Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM
With obesity rates approaching nearly 1 in 2 Americans, the true measure of GLP-1 medications success wont only be their scientific breakthrough but whether they become widely accessible across socioeconomic boundaries
10.12997/jla.2022.11.1.1 133
N-Acetyl Cysteine naturally contains sulfur and may produce a noticeable sulfur-like scent in supplements
Diabetes, Obesity & Metabolism, 16 ,